FrancophonIA/ELRC3.0 huggingface dataset:
English: The powder is the active substance 13C-urea (45 mg for children or 75 mg for adults).
Maltese: It-trab huwa s-sustanza attiva 13C-urea (45 mg għat-tfal jew 75 mg għall adulti).
English: This document is a summary of the European Public Assessment Report (EPAR).
Maltese: RAPPORT TA' VALUTAZZJONI PUBBLIKA EWROPEA (EPAR)
English: This summary was last updated in 09-2007.
Maltese: Dan is-sommarju ġie aġġornat l-aħħar f'09-2007.
English: The active substance in Helicobacter Test INFAI, 13C-urea, is the natural chemical urea that has been labelled with carbon-13 (13C).
Maltese: Is-sustanza attiva, 13C-urea, fit-Test Helicobacter INFAI, hija l-urea kimika naturali li ġiet ittikkettjata bil-karbonju-13 (13C).
English: This labelled carbon dioxide can be measured by specialised laboratories using a technique called mass spectrometry.
Maltese: Dan id-dijossidu tal-karbonju ittikkettjat jista' jitkejjel minn laboratorji speċjalizzati bl-użu ta' teknika msejħa spektometrija talmassa.
English: Helicobacter Test INFAI has been tested in four studies in adult patients involving a total of 561 patients and one study in 335 children and adolescents.
Maltese: It-Test Helicobacter INFAI ġie studjat f'erba' studji f'pazjenti adulti li involvew total ta' 561 pazjent u studju bi 335 tifel u tifla u adolexxenti.
English: The marketing authorisation was renewed on 14 August 2002 and 14 August
Maltese: L-awtorizzazzjoni għat-tqegħid fis-suq ġiet imġedda fl-14 ta' Awwissu 2002 u fl-14 ta' Awwissu 2007.
English: This means that it contains 13C, a rare form of the carbon atom, instead of carbon-12 (12C), the form that is the most common in nature.
Maltese: Dan ifisser li fiha 13C, forma rari ta' l-atomu tal-karbonju, minflok karbonju-12 (12C), il-forma li hija l-aktar komuni fin-natura.
English: Helicobacter Test INFAI can be used to test adults, adolescents who are likely to have peptic ulcer disease, and children aged three to 11 years.
Maltese: It-Test Helicobacter INFAI jista' jintuża biex jittestja lill-adulti, adolexxenti bi probabbiltà li għandhom mard ta' ulċeri peptiċi, u tfal ta' etajiet minn tlieta sa 11-il sena.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Helicobacter Test INFAI to INFAI, Institut für biomedizinische Analytik & NMR-Imaging GmbH on 14 August 1997.
Maltese: Il-Kummissjoni Ewropea tat awtorizzazzjoni għat-tqegħid fis-suq valida madwar l-Unjoni Ewropea kollha għal Helicobacter Test INFAI lil INFAI, Institut für biomedizinische Analytik & NMRImaging GmbH fl-14 ta' Awwissu 1997.
English: EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR) HELICOBACTER TEST INFAI EPAR summary for the public
Maltese: T-TEST HELICOBACTER INFAI Sommarju ta' l-EPAR għall-pubbliku
English: Helicobacter Test INFAI is a diagnostic test.
Maltese: It-Test Helicobacter INFAI huwa test dijanjostiku.
English: H. pylori is a bacterium that is a factor in diseases such as dyspepsia (heartburn, bloating and nausea), gastritis (inflammation of the stomach), and peptic ulcer disease (ulcers in the stomach or the duodenum).
Maltese: H. pylori huwa batterju li huwa fattur f'mard bħal dispepsja (ħruq ta' stonku, tinfiħ u nawżja), gastrite (infjammazzjoni ta' l-istonku) u mard ta' ulċeri peptiċi (ulċeri fl-istonku jew fid-duwodenu).
English: The Committee for Medicinal products for Human Use (CHMP) decided that Helicobacter Test INFAI's benefits are greater than its risks for the in vivo diagnosis of gastroduodenal H. pylori infection in adults, adolescents who are likely to have peptic ulcer disease, and children aged three to 11 years for the evaluation of the success of eradication treatment, or when invasive tests cannot be performed, or when there are discordant results arising from invasive tests.
Maltese: Il-Kumitat għall-Prodotti Mediċinali għall-Użu mill-Bniedem (CHMP) iddeċieda li l-benefiċċji tatTest Helicobacter INFAI's huma akbar mir-riskji tiegħu għad-dijanjożi in vivo ta' infezzjoni H. pylori gastroduwodenali fl-adulti, adolexxenti li x'aktarx ikollhom mard ta' ulċeri peptiċi, u tfal ta' etajiet minn tlieta sa 11-il sena għall-evalwazzjoni tas-suċċess tal-kura ta' qerda, jew meta testijiet invażivi ma jkunux jistgħu jsiru, jew meta jkun hemm riżultati diskordanti ġejjin minn testijiet invażivi.
English: Helicobacter Test INFAI is used to diagnose Helicobacter pylori infection in the stomach and duodenum (the part of the gut just below the stomach).
Maltese: It-Test Helicobacter INFAI jintuża biex tiġi dijanjotizzata infezzjoni Helicobacter pylori fl-istonku u d-duwodenu (il-parti tal-musrana eżatt taħt l-istonku).
English: The patient then takes a ‘test meal' (either 200 ml of pure orange juice or 1 g of citric acid dissolved in 200 ml water), followed by the solution of Helicobacter Test INFAI dissolved in water.
Maltese: Il-pazjent imbagħad jieħu ‘ikla tat-test' (jew 200 ml ta' meraq tal-larinġ pur jew gramma ta' aċidu ċitriku maħlul f'200 ml ilma), segwita minn soluzzjoni tat-Test Helicobacter INFAI maħlul fl-ilma.
English: When the patient takes Helicobacter Test INFAI, the 13C-urea contained in the test is broken down by H Pylori into carbon dioxide that also contains 13C.
Maltese: Meta l-pazjent jieħu t-Test Helicobacter INFAI, l-13C-urea li fih it-test titkisser minn H Pylori f'dijossidu tal-karbonju li fih ukoll 13C.
English: In children aged three to 11 years, the ‘test meal' should be 100 ml of pure orange juice.
Maltese: Fi tfal ta' etajiet bejn tlieta sa 11-il sena, l‘ikla tat-test' għandha tkun 100 ml ta' meraq tal-larinġ pur.
English: What is the risk associated with Helicobacter Test INFAI?
Maltese: X'inhu r-riskju assoċjat mat-Test Helicobacter INFAI?
English: All received 75 mg of 13C-urea, except 204
Maltese: Huma kollha irċievew 75 mg ta' 13C-urea, ħlief 204 tifel u tifla taħt l-età ta' 11-il sena li irċievew 45 mg.
English: Helicobacter Test INFAI is a breath test: breath samples are collected, which are then sent out for analysis to a specialised laboratory.
Maltese: It-Test Helicobacter INFAI huwa test tan-nifs: jinġabru kampjuni tan-nifs, li imbagħad jintbagħtu għal analiżi fl-laboratorju speċjalizzat.
English: Other information about Helicobacter Test INFAI:
Maltese: Tagħrif ieħor dwar T-Test Helicobacter INFAI:
English: What is Helicobacter Test INFAI?
Maltese: Kif jintuża t-Test Helicobacter INFAI?
English: H. pylori contain enzymes called ureases that make it able to break down urea into carbon dioxide, which is then removed in the breath.
Maltese: H. pylori fih enzimi msejħa ureases li jagħmluh kapaċi li jkisser l-urea f'dijossidu tal-karbonju, li imbagħad jitneħħa man-nifs.
English: If there is labelled carbon dioxide in the breath sample after 30 minutes (a positive test), this means that the patient is infected with H. pylori.
Maltese: Jekk wara 30 minuta ikun hemm dijossidu tal-karbonju ittikkettjat fil-kampjun tan-nifs (test pożittiv), dan ifisser li l-pazjent huwa nfettat b'H. pylori.
English: In all studies, the results of the test done using Helicobacter Test INFAI agreed with the results obtained with the endoscopy and histology in over 95% of cases.
Maltese: Fl-istudji kollha, ir-riżultati tat-test magħmul bl-użu tat-Test Helicobacter INFAI qablu mar-riżultati miksuba bl-endoskopija u l-istoloġija f'aktar minn 95% tal-każijiet.
English: How does Helicobacter Test INFAI work?
Maltese: Kif ġie studjat it-Test Helicobacter INFAI?
English: Why has Helicobacter Test INFAI been approved?
Maltese: Għalfejn ġie approvat it-Test Helicobacter INFAI?
English: In all studies, patients underwent an endoscopy and histology (when a probe is inserted in the stomach to take a sample and the sample is then analysed) as well as a breath test with Helicobacter Test INFAI, and the results of the two tests were compared.
Maltese: Fl-istudji kollha, il-pazjenti saritilhom endoskopija u istoloġija (meta s-sonda tiddaħħal fl-istonku biex tieħu kampjun u l-kampjun huwa mbagħad analizzat) kif ukoll test tan-nifs bit-Test Helicobacter INFAI, u r-riżultati taż-żewġ testijiet kienu mqabbla.
English: Helicobacter Test INFAI should not be used in patients who have, or may have gastric (stomach) infection or atrophic gastritis (stomach inflammation that causes the breakdown of the stomach lining), as these might interfere with the breath test.
Maltese: It-Test Helicobacter INFAI m'għandux jintuża f'pazjenti li għandhom, jew jista' jkollhom infezzjoni gastrika (ta' l-istonku) jew gastrite atrofika (infjammazzjoni ta' l-istonku li tikkaġuna tkissir tar-rita ta' l-istonku), peress li dawn jistgħu jinterferixxu mat-test tan-nifs.
English: Thrombotic Thrombocytopenic Purpura (TTP)
Maltese: Pupura Tromboċitopenika Trombotika (Thrombotic Thrombocytopenic Purpura - TTP)
English: Proton Pump Inhibitors (PPI):
Maltese: Impedituri tal-Proton Pump (Proton Pump Inhibitors, PPI):
English: KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenia TAD Pharma GmbH, Heinz-Lohmann-Straße 5, 27472 Cuxhaven, Germany Pharmachemie B.V., Swensweg 5, 2031 GA Haarlem, The Netherlands
Maltese: KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Is-Slovenja TAD Pharma GmbH, Heinz-Lohmann-Straße 5, 27472 Cuxhaven, il-Ġermanja Pharmachemie B.V., Swensweg 5, 2031 GA Haarlem, L-Olanda
English: Österreich ratiopharm Arzneimittel Vertriebs-GmbH Tel: +43/1/97007-0
Maltese: ratiopharm Arzneimittel Vertriebs-GmbH Tel: +43/1/97007-0
English: • Tablet coating: Polyvinyl alcohol, titanium dioxide (E171), red iron oxide (E172), yellow iron oxide (E172), talc and macrogol 3000.
Maltese: • Fil-kisi tal-pillola Polyvinyl alcohol, titanium dioxide (E171), red iron oxide (E172), yellow iron oxide (E172), talc u macrogol 3000.
English: Teva Italia S.r.l Tel: +(39) 028917981
Maltese: Italia S.r.l Tel: +(39) 028917981
English: Date of latest renewal: 8 May 2014
Maltese: Data tal-ewwel awtorizzazzjoni: 21 ta' Settembru 2009 Data tal-aħħar tiġdid: 8 ta' Mejju 2014
English: In CURE, 823 (6.6%) patients received concomitant GPIIb/IIIa receptor antagonist therapy.
Maltese: F'CURE, 823 (6.6%) pazjent ingħataw terapija ta' antagonista għar-riċetturi GPIIb/IIIa fl-istess ħin.
English: EU/1/09/561/001 7 film-coated tablets EU/1/09/561/002 14 film-coated tablets EU/1/09/561/003 28 film-coated tablets EU/1/09/561/004 30 film-coated tablets EU/1/09/561/005 50 film-coated tablets EU/1/09/561/006 56 film-coated tablets EU/1/09/561/007 84 film-coated tablets EU/1/09/561/008 90 film-coated tablets EU/1/09/561/009 100 film-coated tablets EU/1/09/561/010 28x1 film-coated tablets EU/1/09/561/011 50x1 film-coated tablets
Maltese: EU/1/09/561/001 7 pilloli miksija b'rita EU/1/09/561/002 14-il pillola miksija b'rita EU/1/09/561/003 28 pillola miksija b'rita EU/1/09/561/004 30 pillola miksija b'rita EU/1/09/561/005 50 pillola miksija b'rita EU/1/09/561/006 56 pillola miksija b'rita EU/1/09/561/007 84 pillola miksija b'rita EU/1/09/561/008 90 pillola miksija b'rita EU/1/09/561/009 100 pillola miksija b'rita EU/1/09/561/010 28x1 pillola miksija b'rita EU/1/09/561/011 50x1 pillola miksija b'rita
English: INFORMATION IN BRAILLE Clopidogrel Teva Pharma 75 mg
Maltese: INFORMAZZJONI BIL-BRAILLE Clopidogrel Teva Pharma 75 mg
English: • Pharmacovigilance system
Maltese: • Is-sistema ta' farmakoviġilanza
English: Clopidogrel and the main circulating (inactive) metabolite bind reversibly in vitro to human plasma proteins (98 % and 94 % respectively).
Maltese: Clopidogrel u l-metabolit (mhux attiv) ċirkolanti prinċipali jintrabtu b'mod riversibbli in vitro malproteini umani tal-plażma (98% u 94% rispettivament).
English: In poor metabolisers, active metabolite exposure was decreased by 63-71% compared to extensive metabolisers.
Maltese: F'metabolizzaturi batuti, l-espożizzjoni attiva għall-metabolit tnaqqset minn 63-71% meta mqabbla ma' metabolizzaturi estensivi.
English: The use of clopidogrel in CURE was associated with a decrease in the need of thrombolytic therapy (RRR = 43.3%; CI: 24.3%, 57.5%) and GPIIb/IIIa inhibitors (RRR = 18.2%; CI: 6.5%, 28.3%).
Maltese: L-użu ta' clopidogrel fi CURE kien assoċjat mat-tnaqqis fil-bżonn ta' kura trombolitika (RRR=43.3%; CI: 24.3%, 57.5%) u inibituri ta' GPIIb/IIIa (RRR=18.2%; CI: 6.5%, 28.
English: Retroperitoneal haemorrhage
Maltese: Emorraġija retroperitonea li
English: A total of 99.7% of patients received fibrinolytics (fibrin specific: 68.7%, non-fibrin specific: 31.1%), 89.5% heparin, 78.7% beta blockers, 54.7% ACE inhibitors and 63% statins.
Maltese: Ittotal ta' 99.7% tal-pazjenti rċevew is-sustanzi fibrinolitiċi (speċifiċi ghall-fibrin: 68.7%, mhux speċifiċi għall-fibrina: 31.1%), 89.5% heparin, 78.7% imblokkaturi tar-riċetturi beta, 54.7% l-inibituri ACE u 63% statins.
English: While you are taking Clopidogrel Teva Pharma:
Maltese: Waqt li qed tieħu Clopidogrel Teva Pharma:
English: Medicinal products that are strong or moderate CYP2C19 inhibitors include, for example, omeprazole and esomeprazole, fluvoxamine, fluoxetine, moclobemide, voriconazole, fluconazole, ticlopidine, carbamazepine, and efavirenz.
Maltese: Mediċini li huma inibituri qawwijin jew moderati ta' CYP2C19 jinkludu, pereżempju, omeprazole u esomeprazole, fluvoxamine, fluoxetine, moclobemide, voriconazole, fluconazole, ticlopidine, carbamazepine u efavirenz.
English: There have been a number of retrospective analyses, however, to evaluate this effect in patients treated with clopidogrel for whom there are genotyping results: CURE (n=2721), CHARISMA (n=2428), CLARITY-TIMI 28 (n=227), TRITON-TIMI 38 (n=1477), and ACTIVE-A (n=601), as well as a number of published cohort studies.
Maltese: CURE (n=2721), CHARISMA (n=2428), CLARITY-TIMI 28 (n=227), TRITON-TIMI 38 (n=1477) u ACTIVE-A (n=601), kif ukoll bħala numru ta' studji ta' koorti ppubblikati
English: The population included 27.8% women, 58.4% patients ≥ 60 years (26% ≥ 70 years) and 54.5% patients who received fibrinolytics.
Maltese: Il-grupp studjat inkluda 27.8% nisa, 58.4% pazjenti ≥60 sena (26% ≥70 sena) u 54.5% tal-pazjenti li rċevew issustanzi fibrinolitiċi.
English: This was associated with a reduction of the mean inhibition of platelet aggregation by 15% and 11%, respectively.
Maltese: Dan kien assoċjat ma tnaqqis fl-impediment medju ta' aggregazzjoni bi 15% u 11% rispettivament.
English: Thrombotic thrombocytopenic purpura (TTP) (see section 4.4), aplastic anaemia, pancytopenia, agranulocytosis, severe thrombocytopenia, acquired haemophilia A, granulocytopenia, anaemia
Maltese: Purpura tromboċitopenikatrombotika (thrombotic thrombocytopenic purpura (TTP)) (ara sezzjoni 4.4), anemija aplastika, panċitopenija, agranuloċitosi, tromboċitopenija severa, emofilja A akkwiżita, granuloċitopenija, anemija
English: • Tablet core: microcrystalline cellulose, colloidal anhydrous silica, crospovidone (type A), macrogol 6000 and hydrogenated castor oil
Maltese: • Fil-qalba tal-pillola: microcrystalline cellulose, colloidal anhydrous silica, crospovidone (tip A), macrogol 6000 u żejt ir-riġnu idroġenat u
English: The CYP2C19*1 allele corresponds to fully functional metabolism while the CYP2C19*2 and CYP2C19*3 alleles are nonfunctional.
Maltese: L-allel CYP2C19*1 jikkorispondi għal metaboliżmu funzjonali sħiħ waqt li l-alleli CYP2C19*2 u CYP2C19*3 mhuwiex funzjonali.
English: Perforated unit dose blister of OPA/Al/PVC-Al containing 28x1 and 50x1 film-coated tablets in the box.
Maltese: Folja perforata ta' doża waħda tal-OPA/Al/PVC-Al li fiha 28x1 u 50x1 pillola miksija b'rita f'kaxxa.
English: Other alleles associated with absent or reduced metabolism are less frequent and include CYP2C19*4, *5, *6, *7, and *8.
Maltese: Alleli oħra assoċjati ma' metaboliżmu nieqes jew imnaqqas huma inqas frekwenti u jinkludu CYP2C19*4, *5, *6, *7 u *8.
English: The CYP2C19*2 and CYP2C19*3 alleles account for the majority of reduced function alleles in Caucasian (85%) and Asian (99%) poor metabolisers.
Maltese: L-alleli CYP2C19*2 u CYP2C19*3 jgħoddu għall-maġġoranza ta' alleli b'funzjoni mnaqqsa fil-bniedem Kawkasi (85%) u 99% f'metabolizzaturi batuti Ażjatiċi.
English: The decrease was associated with a 39% (loading dose) and 21% (maintenance dose) reduction of inhibition of platelet aggregation.
Maltese: In-tnaqqis kien assoċjat b'39% (doża inizjali) u 21% (doża ta' manteniment) tnaqqis fl-impediment ta' aggregazzjoni ta' plejtlits.
English: - fluconazole or voriconazole, medicines to treat fungal infections, - efavirenz, a medicine to treat HIV (human immunodeficiency virus) infections, - carbamazepine, a medicine to treat some forms of epilepsy, - moclobemide, medicine to treat depression, - repaglinide, medicine to treat diabetes, - paclitaxel, medicine to treat cancer.
Maltese: - efavirenz, mediċina għat-trattament tal-infezzjonijiet mill-HIV (virus tal-immunodefiċjenza umana), - carbamazepine, mediċina użata għall-kura ta' xi forom ta' epilessija, - moclobemide, mediċini li jikkuraw id-dipressjoni, - repaglinide, mediċina għat-trattament tad-dijabete, - paclitaxel, mediċina għat-trattament tal-kanċer.
English: TEVA PHARMA, S.L.U Tel: +(34) 91 387 32 80
Maltese: L.U Tel: +(34) 91 387 32 80
English: After the 300 mg/75 mg dose regimen, antiplatelet responses were decreased in the poor metabolisers with mean IPA (5 μM ADP) of 24% (24 hours) and 37% (Day 5) as compared to IPA of 39% (24 hours) and 58% (Day 5) in the extensive metabolisers and 37% (24 hours) and 60% (Day 5) in the intermediate metabolisers.
Maltese: Wara l-programm ta' kura ta' 300 mg/75 mg, risponsi kontra l-plejtlits tnaqqsu fil-metabolizzaturi batuti b'IPA medju (5 μM ADP) ta' 24% (24 siegħa) u 37% (Jum 5) meta mqabbel ma' IPA ta' 39% (24 siegħa) u 58% (Jum 5) fil-metabolizzaturi estensivi u 37% (24 siegħa) u 60% (Jum 5) fil-metabolizzaturi intermedjarji.
English: 7 film-coated tablets 14 film-coated tablets 28 film-coated tablets 30 film-coated tablets 50 film-coated tablets 56 film-coated tablets 84 film-coated tablets 90 film-coated tablets 100 film-coated tablets 28x1 film-coated tablets 50x1 film-coated tablets
Maltese: 7 pilloli miksija b'rita 14-il pillola miksija b'rita 28 pillola miksija b'rita 30 pillola miksija b'rita 50 pillola miksija b'rita 56 pillola miksija b'rita 84 pillola miksija b'rita 90 pillola miksija b'rita 100 pillola miksija b'rita 28x1 pillola miksija b'rita 50x1 pillola miksija b'rita
English: CYP2C8 substrate medicinal products: Clopidogrel has been shown to increase repaglinide exposure in healthy volunteers.
Maltese: Prodotti mediċinali sustrati ta' CYP2C8: intwera f'volontiera b'saħħithom, li clopidogrel iżid lespożizzjoni ta' repaglinide.
English: A crossover study in 40 healthy subjects, 10 each in the four CYP2C19 metaboliser groups (ultrarapid, extensive, intermediate and poor), evaluated pharmacokinetic and antiplatelet responses using 300 mg followed by 75 mg/day and 600 mg followed by 150 mg/day, each for a total of 5 days (steady state).
Maltese: Studju inkroċjat ta' 40 individwu b'saħħithom, 10 kull wieħed fl-erba' gruppi tal-metabolizzatur ta' CYP2C19 (ultrarapidu, estensiv, intermedjarju u batut), ivvalorizza r-risponsi farmakokinetiċi u kontra l-plejtlits meta ngħataw 300 mg segwiti minn 75 mg /jum u 600 mg segwiti minn 150 mg/jum, kull wieħed għal total ta' 5 ijiem (stat fiss).
English: CYP2C19 is involved in the formation of both the active metabolite and the 2-oxo-clopidogrel intermediate metabolite.
Maltese: CYP2C19 hu involut fil-formazzjoni kemm tal-metabolit attiv u tal-metabolit intermedjarju 2-oxoclopidogrel.
English: Posology • Adults and elderly
Maltese: • Adulti u anzjani
English: The number of patients experiencing the primary endpoint [cardiovascular (CV) death, myocardial infarction (MI), or stroke] was 582 (9.3%) in the clopidogrel-treated group and 719 (11.4%) in the placebo-treated group, a 20% relative risk reduction (95% CI of 10%-28%; p=0.00009) for the clopidogrel-treated group (17% relative risk reduction when patients were treated conservatively, 29% when they underwent percutaneous transluminal coronary angioplasty (PTCA) with or without stent and 10% when they underwent coronary artery bypass graft (CABG)).
Maltese: In-numru ta' pazjenti li għaddew mill-punt primarju ta' tmiem [mewt kardjovaskulari (CV), infart mijokardijaku (MI) jew puplesija] kien 582 (9.3%) fil-grupp ikkurat bi clopidogrel u 719 (11.4%) filgrupp ikkurat bil-plaċebo, li jissarraf fi tnaqqis fir-riskju relattiv ta' 20% (95% CI ta' 10%-28%; p=0.00009) għall-grupp ikkurat bi clopidogrel (tnaqqis fir-riskju relattiv ta' 17% f'pazjenti li kienu kkurati b'mod konservattiv, 29% meta kellhom anġoplastija koronarja transluminali perkutanja (PTCA) bi stent jew mingħajru u 10% meta kellhom trapjant ta' bajpass f'arterja koronarja (CABG)).
English: Their frequency is defined using the following conventions: common ( 1/100 to <1/10); uncommon ( 1/1,000 to < 1/100); rare (1/10,000 to <1/1,000); very rare (<1/10,000), not known (cannot be estimated from the available data).
Maltese: Il-frekwenza tagħhom hi definita skont dawn il-konvenzjonijiet: komuni (≥1/100 sa <1/10); mhux komuni (≥1/1,000 sa <1/100); rari (≥1/10,000 sa <1/1,000); rari ħafna (<1/10,000); mhux magħruf (ma tistax tiġi stmata mit-tagħrif disponibbli).
English: In vitro and in vivo, clopidogrel is metabolised according to two main metabolic pathways: one mediated by esterases and leading to hydrolysis into its inactive carboxylic acid derivative (85% of circulating metabolites), and one mediated by multiple cytochromes P450.
Maltese: In vitro u in vivo, clopidogrel jiġi metabolizzat f'żewġ passaġġi metaboliċi ewlenin: wieħed permezz ta' esterases u li jwassal għallidrolisi fid-derivat mhux attiv ta' carboxylic acid (85% ta' metaboliti ċirkolanti), u l-passaġġ l-ieħor li jsir permezz ta' cytochromes multipli ta' P450.
English: MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS BLISTER (7, 14, 28, 30, 50, 56, 84, 90, 100, 50x1 film-coated tablets)
Maltese: FOLJA (7, 14, 28, 30, 50, 56, 84, 90, 100, 50x1 pillola miksija b'rita)
English: Boxes of 7, 14, 28, 30, 50, 56, 84, 90 and 100 film-coated tablets in blisters or boxes of 28x1 and 50x1 film-coated tablets in perforated unit dose blisters are available.
Maltese: Kaxxi disponibbli f'7, 14, 28, 30, 50, 56, 84, 90 u 100 pillola miksija b'rita ġo folji jew kaxxi ta' 28x1 u 50x1 pilloli miksija b'rita ġo folji perforati ta' doża waħda.
English: Tel: +44(0) 1977 628500
Maltese: United Kingdom Teva UK Limited Tel: +44(0) 1977 628500
English: Pharmacotherapeutic group: Antithrombotic agents, platelet aggregation inhibitors excl. heparin, ATC Code: B01AC-04.
Maltese: Sustanzi antitrombotiċi, inibituri tal-aggregazzjoni tal-plejtlets li jeskludu heparin, Kodiċi ATC:
English: Absorption is at least 50%, based on urinary excretion of clopidogrel metabolites.
Maltese: L-assorbiment huwa mill-inqas ta' 50 %, skont l-eliminazzjoni fl-urina tal-metaboliti ta' clopidogrel.
English: Tests are available to determine a patient's CYP2C19 genotype.
Maltese: Hemm tests disponibbli sabiex jidentifikaw il-ġenotip ta' CYP2C19.
English: No substantial differences in active metabolite exposure and mean inhibition of platelet aggregation (IPA) were observed between ultrarapid, extensive and intermediate metabolisers.
Maltese: Ma dehrux differenzi sostanzjali fl-espożizzjoni attiva talmetabolit u l-impediment medju ta' aggregazzjoni ta' plejtlits (IPA) bejn il-metabolizzaturi ultrarapidi, estensivi u intermedjarji.
English: The number of patients experiencing the co-primary endpoint (CV death, MI, stroke or refractory ischaemia) was 1,035 (16.5%) in the clopidogrel-treated group and 1,187 (18.8%) in the placebo-treated group, a 14% relative risk reduction (95% CI of 6%-21%, p=0.0005) for the clopidogrel-treated group.
Maltese: In-numri ta' pazjenti li kellhom punt ko-primarju ta' tmiem (mewt b'CV, MI, puplesija jew iskemija li mhux qed tirrisondi għall-kura) kien 1,035 (16.5%) fil-grupp ikkurat bi clopidogrel u 1,187 (18.7%) fil-grupp ikkurat bil-plaċebo, tnaqqis ta' 14% fir-riskju relattiv) (95% CI ta' 6%-21%, p=0.0005) għall-grupp ikkurat bi clopidogrel.